Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00275288
Other study ID # 0407M62321
Secondary ID
Status Completed
Phase N/A
First received January 10, 2006
Last updated November 1, 2010
Start date January 2005
Est. completion date June 2007

Study information

Verified date November 2010
Source University of Minnesota - Clinical and Translational Science Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

MRI Study for females ages 18-45 with Borderline Personality Disorder(BPD): This study is a non-treatment study that involves 2 visits. Study Hypothesis:

1. To refine and pilot test functional neuroimaging paradigms to assess the amygdala response to neutral facial expressions across positive and negative emotional contexts.

2. To assess whether patients with borderline personality disorder show a heightened amygdala response to neutral facial expressions relative to healthy controls (20 female healthy controls, 20 females with borderline personality disorder).

3. To assess the relationship between individual differences in clinical ratings of personality and affective regulation, and the amygdala response to facial expressions.


Description:

The first visit will be an interview assessment and will take place at the Ambulatory Research Center (ARC), Fairview University-Riverside Campus. In addition to the interview assessment, we will ask you to complete a set of questionnaires about your behavior and mood. This first visit will last approximately 2.5-3 hours. Following the interview assessment, if you are eligible for the MRI study we will contact you to schedule an MRI scan on a separate visit. This visit will last approximately 2 hours. At this visit you will have an MRI scan of your brain. Prior to the MRI scan, you will have a practice session in an MRI simulator.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

Female subjects ages 18-45 whom meet criteria for BPD will be included in the study. The healthy controls will also be females between the ages 18-45. The healthy controls will undergo the same diagnostic and symptom evaluations as the female patients - these interview schedules will be used mainly for determining exclusion criteria.

Exclusion Criteria:

1. Neither borderline personality disorder subjects or healthy controls may have a history of schizophrenia, schizoaffective disorder, bipolar illness, major depression with psychotic features, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), or Generalized Anxiety Disorder (GAD).

2. Patients and healthy controls may not have a serious neurologic or other metabolic disorder or any medical condition or treatment known to affect the parameters of this study.

3. Neither patients nor healthy controls will be included in the study if they are receiving a medical treatment that requires a medication that may have psychotropic effects.

4. Neither patients nor healthy controls can have any contraindications to MRI scanning such as a metal implant, a pacemaker, or a history of claustrophobia. At the Center for Magnetic Resonance Research (CMRR), we have developed a highly specific and detailed questionnaire to ensure the safety of all participants. This questionnaire is administered prior to any and all scans.

5. Pregnant women will be excluded from the study. This will be assessed by history, date of last menstrual period and urine pregnancy test if necessary.

6. Neither patients nor healthy controls who fulfill criteria for developmental deficiency will be included.

7. Healthy controls with more than two borderline personality disorder criteria will not be eligible for study. This is to reduce the possibility of healthy controls being "near misses" to the patients and diminishing the possibility of finding difference between the patients and the healthy controls.

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States University of Minnesota, Dept of Psychiatry Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To refine and pilot test functional neuroimaging paradigms to assess the amygdala response to neutral facial expressions across positive and negative emotional contexts. To refine and pilot test functional neuroimaging paradigms to assess the amygdala response to neutral facial expressions across positive and negative emotional contexts.
To assess whether patients with borderline personality disorder show a heightened amygdala response to neutral facial expressions relative to healthy controls (20 female healthy controls, 20 females with borderline personality disorder).
To assess the relationship between individual differences in clinical ratings of personality and affective regulation, and the amygdala response to facial expressions
2 years No
Secondary Secondary Outcomes 2) To assess whether patients with borderline personality disorder show a heightened amygdala response to neutral facial expressions relative to healthy controls (20 female healthy controls, 20 females with borderline personality disorder).
3) To assess the relationship between individual differences in clinical ratings of personality and affective regulation, and the amygdala response to facial expressions.
2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Active, not recruiting NCT04587518 - Five Factor Model Treatment for Borderline Personality Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT03677037 - The Short-Term MBT Project Phase 3
Not yet recruiting NCT05989529 - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed NCT02068326 - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial N/A
Completed NCT02518906 - Evaluation of AIT Study N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT02108990 - Acetaminophen and Social Processes Phase 2
Not yet recruiting NCT01683136 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder N/A
Completed NCT01635556 - Evaluation of a Modified Dialectical Behavior Therapy Program N/A
Completed NCT02988037 - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study N/A
Completed NCT02397031 - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder N/A
Terminated NCT01103180 - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Phase 2
Terminated NCT01212588 - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Phase 2
Terminated NCT00539188 - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Phase 2
Recruiting NCT05398627 - Neurofeedback for Borderline Personality Disorder N/A
Recruiting NCT03994510 - SHame prOpensity in bOrderline Personality Disorder N/A
Recruiting NCT06005129 - Personality Change Study for Borderline Personality Disorder N/A